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Abstract
Cardiogenic shock has a poor prognosis with established treatment strategies. We report a 62 years old man with heart 
failure exacerbating into refractory cardiogenic shock successfully treated with the combination of a percutaneous left 
ventricular assist device (LVAD) and subacute cardiac resynchronization therapy (CRT) implantable cardioverter-
defibrillator device (CRT-D).
Background
The mortality rate in patients with cardiogenic shock is
still very high [1]. Medical therapy has symptomatic
effects, but has no proven reduction of mortality. Percu-
taneously placed LVAD is an option for selected groups of
these patients. The percutaneous microaxial blood pump,
Impella LP 2.5® (Abiomed; Aachen, Germany) can be rap-
idly deployed with low complication rates and have
improved hemodynamic effects compared with the
intraaortic balloon pump (IABP) [2-4]. Furthermore, in
selected patients with stable heart failure, CRT is proven
to relive symptoms and improve outcomes [5]. The
potential efficiency of acute and subacute CRT treatment
in patients with cardiogenic shock has to our knowledge
not been studied.
Case presentation
A previously healthy 62 years old man who had experi-
enced reduced exercise capacity for the last 6 months was
admitted to the local hospital after 2 weeks of increasing
dyspnoea. Echocardiography revealed biventricular dila-
tation, reduced wall thickness, asynchronous left ventric-
ular (LV) contraction and left ventricular ejection
fraction (LVEF) of 10%. ECG showed left bundle branch
block (QRS width 170 msec). The clinical condition dete-
riorated rapidly into a cardiogenic shock. Multiorgan fail-
ure developed including hepatic dysfunction and renal
impairment. The following day, he was transferred to our
hospital for LVAD therapy. An Impella LP 2.5® was percu-
taneously deployed, and the mean arterial pressure
immediately improved from 50 mmHg to 70 mmHg and
the vasopressor drugs could be stopped. Coronary
angiography showed normal coronary arteries. The
patient clinically improved and INR and s-creatinine nor-
malized during the first three days.
After five days LVEF was still only 10% and blood pres-
sure could not be sustained without LVAD support. Due
to refractory decompensated heart failure and severe
asynchronous LV contraction with left bundle branch
block, a CRT-D (Medtronic Insync Sentry 7298) was
implanted on vital indication. The procedure was compli-
cated by pericardial tamponade not responding to peri-
cardiocentesis. Sternotomy was required to repair a
perforation of the right atrium with direct suture. In
order to permit prolonged LAVD support and increase
pump delivery, Impella LP2.5® was on day 6 after admis-
sion replaced through a surgical incision with an Impella
LP 5.0® with a maximum flow rate of 5.0/min (Figure 1).
Ventilator treatment and LVAD support were continued
for a total of 22 days. Transient infections were treated
with antibiotics. There were no signs of renal impair-
ment, central neurological deficits or mental impairment.
The CRT-D was optimized by adjustments of the atrio-
ventricular delay and interventricular timing of pacing
guided by echocardiography. At outpatient control after
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four months the patient was in New York Heart Associa-
tion (NYHA) functional class IIb with LVEF of 22% and
maximal oxygen uptake during exercise was 13.9 ml/kg/
min.
Discussion
In the reported case, the patient presented with untreated
severe decompensated dilated cardiomyopathy with
hemodynamic instability exacerbating into cardiogenic
shock refractory to standard intensive medical treatment.
IABP has been the most widely used mechanical hemo-
dynamic assist device. In spite of beneficial hemodynamic
effects and a low complication rate, no randomized clini-
cal studies have shown reduction of mortality [2]. Other
available hemodynamic support strategies include surgi-
cal cardiopulmonary support (CPS) and different percu-
taneous LVAD systems (i.e. the TandemHeart® and the
Impella LP 2.5/5.0®). The Impella LP 2.5® is inserted via
the femoral artery and advanced retrogradly into the left
ventricle. An electromagnetic motor draws blood from
the inflow port in the left ventricle to the outflow port in
the proximal ascending aorta close to the inlet of the cor-
onary arteries. Small studies comparing IABP and
Impella in cardiogenic shock may indicate beneficial
hemodynamic effects of the percutaneous LVAD [3,4].
Experimental studies have shown that Impella LP 2.5®
may sustain vital organ perfusion even during cardiac
arrest [6]. Thus, the percutaneous LVAD may have poten-
tial to significantly improve hemodynamics in selected
critically ill patients.
CRT improves symptoms and reduces mortality by 36%
in patients with ischemic and non-ischemic cardiomyo-
pathy in NYHA class III-IV. This is documented for stable
patients on optimal medical therapy with dilated LV,
LVEF ≤ 35% and QRS width > 120 ms [5]. The benefit of
CRT in cardiogenic shock has not been studied. Some
observational studies have reported beneficial outcome
from CRT in inotrope-supported patients with end-stage
heart failure [7,8], and there are case reports on clinical
improvement effected by CRT in patients on IABP sup-
port [9]. The rapid onset of hemodynamic improvement
of CRT may be of clinical benefit in an acute setting and it
is likely that CRT has an additive effect on the unloading
of the left ventricle and improved organ perfusion
achieved by the LVAD in patient with cardiogenic shock.
This should be judged against the elevated risk of compli-
cations using mechanical devices in this group of unsta-
ble patients. The use of LVAD and CRT combined in
cardiogenic shock has to our knowledge not been
reported previously.
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